相关实验视频

Updated: Jun 15, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

纳米点用于急性肺损伤治疗

Jiayang Yan^1,2,3, Zhongmin Tang⁴, Yanan Li^1,2,3

¹Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

|December 12, 2023

概括

纳米点 (MND) 显示出治疗急性肺损伤 (ALI) 的前景,这是急性呼吸系统应急综合征 (ARDS) 中经常出现的情况. 这些纳米粒子有效降低氧化应激和炎症,为肺部疾病提供了潜在的新疗法.

科学领域:

生物医学工程生物医学工程
纳米医学是一种纳米医学.
肺部病理学肺部病理学

背景情况:

急性呼吸困难综合征 (ARDS) 是一个重大的临床挑战,死亡率高,有效治疗方法有限.
COVID-19大流行凸显了对抗ARDS的新型治疗策略的迫切需要.
过度反应性氧物种 (ROS) 和不受控制的炎症是ARDS病变发生的关键驱动因素.

研究的目的:

开发和评估纳米颗粒 (MND) 作为急性肺损伤 (ALI) 的潜在治疗剂.
调查MND在减轻氧化应激和肺部炎症反应方面的有效性.
阐明MND在ALI中的保护作用背后的分子机制.

主要方法:

开发超微型,生物相容的纳米颗粒 (MND).
在ALI的小鼠模型中,MNDs的内给药.
评估肺氧化应激,炎症标志物,蛋白质透性和组织学损伤.
转录组分析以确定受MNDs影响的分子通路.

主要成果:

在ALI小鼠中,MND显著降低了肺氧化应激,炎症和蛋白质泄漏.
组织学检查显示,MND治疗后肺损伤有所改善.
在MND给药后,没有观察到任何重大安全问题.
转录组学确定了NLRP3依赖性热性通路的抑制是MND作用的关键机制.

结论:

纳米点 (MND) 通过清除ROS和减少炎症,证明了急性肺损伤 (ALI) 的显著治疗潜力.
MNDs通过抑制NLRP3炎症酶和 pyroptosis来保护肺组织.
这项研究将MND作为一种有希望的基于纳米材料的治疗候选药物用于ARDS治疗.

关键词:

肺部急性肺损伤是什么急性呼吸道疾病综合征.抗氧化剂抗氧化剂是一种抗氧化剂.合金是一种合金.纳米医药是一种纳米医药.有活性氧物种的反应性氧物种.

更多相关视频

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Inducing Acute Lung Injury in Mice by Direct Intratracheal Lipopolysaccharide Instillation

Published on: July 6, 2019

Manganese Oxide Nanoparticle Synthesis by Thermal Decomposition of ManganeseII Acetylacetonate

Manganese Oxide Nanoparticle Synthesis by Thermal Decomposition of ManganeseII Acetylacetonate

Published on: June 18, 2020

相关概念视频

Acute Respiratory Failure-V

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...

Pneumothorax-I

Pneumothorax-I

A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.